Join the club for FREE to access the whole archive and other member benefits.


AI-driven genetic intronization

ExpressionEdits has secured $13M in seed funding to enhance protein expression using AI-driven intronization technology. This innovative approach optimizes genetic design by integrating introns, crucial for effective gene expression. CEO and co-founder Dr. Kärt Tomberg developed this method during the COVID-19 pandemic, revolutionizing the production of challenging proteins. The company's Genetic Syntax Engine perfects genetic grammar, enabling the creation of high-value therapeutic proteins. ExpressionEdits seeks partnerships to advance gene therapy optimization. Key team members include Dr. Rebecca Godfrey (COO), Dr. Leopold Parts (CTO), and advisors like Prof. Allan Bradley.

Visit website:



Details last updated 07-Jun-2024

ExpressionEdits News

ExpressionEdits secures $13M for developing AI-powered gene therapy

Longevity Technology - 03-Jun-2024

Company aims to improve protein production in genetic medicine